Novo Nordisk Navigates US Market Headwinds & Leadership Shift
Novo Nordisk faces slowing growth, fierce competition from Eli Lilly and copycats in the US, prompting a CEO change and strategic refocus.
This post is for paying subscribers only
Already have an account? Sign in.